Aesica is working with a leading Japanese pharmaceutical company to provide the active ingredient for an antiinflammatory formulation containing S+flurbiprofen. The patch obtained good results in phase 3 clinical trials and in October 2014 a submission was filed for market approval with the Ministry of Health, Labour and Welfare in Japan for the indication of osteoarthritis.
Osteoarthritis is a chronic degenerative disease of the joints. The number of patients in Japan is estimated to be 24 million for osteoarthritis of the knee joint and 35 million for lumbar spondylosis, with approximately 30% of these patients showing symptoms of pain. Considering that pain is a major cause of reduced quality of life (QOL), there are high hopes for the development of formulations that possess a powerful anti-inflammatory analgesic action.
Aesica is a leading supplier of the active ingredient flurbiprofen and the modified S+flurbiprofen, and has supplied the product into the Japanese market for many years. Demand for the new formulation is expected to grow steadily from 2016.